Switching from Saxagliptin to Sitagliptin in Patients with Renal Impairment and Pancreatitis History

Primary Recommendation Based on Clinical Context

• The American Heart Association recommends that saxagliptin should be used with caution in patients at risk for heart failure, including those with renal impairment 1
• Saxagliptin increased heart failure hospitalization by 27% (HR 1.27, 95% CI 1.07-1.51) in the SAVOR-TIMI 53 trial 2

Cardiovascular Safety Profile: Critical Reason for Switching

• Sitagliptin demonstrated cardiovascular safety with neutral heart failure risk (HR 1.00, 95% CI 0.83-1.20) in the TECOS trial 2
• The American College of Cardiology recommends considering the cardiovascular safety profile when selecting a DPP-4 inhibitor, such as sitagliptin, for patients with renal impairment and pancreatitis history 1

Alternative Consideration: Linagliptin

• Linagliptin showed neutral cardiovascular safety (HR 1.02, 95% CI 0.89-1.17) and neutral heart failure risk (HR 0.90, 95% CI 0.74-1.08) in the CARMELINA trial 2
• The European Association for the Study of Diabetes recommends linagliptin as an alternative to sitagliptin for patients with severe renal impairment, as it requires no dose adjustment regardless of renal function 2

Critical Monitoring Requirements

• The American Diabetes Association recommends monitoring for signs and symptoms of heart failure, particularly if the patient has pre-existing cardiac risk factors, after switching to sitagliptin or linagliptin 1
• The patient should be educated to report severe abdominal pain that could indicate pancreatitis, as both saxagliptin and sitagliptin carry a similar pancreatitis risk 3